MX345697B - Formulaciones de rifaximina y usos de las mismas. - Google Patents

Formulaciones de rifaximina y usos de las mismas.

Info

Publication number
MX345697B
MX345697B MX2013000522A MX2013000522A MX345697B MX 345697 B MX345697 B MX 345697B MX 2013000522 A MX2013000522 A MX 2013000522A MX 2013000522 A MX2013000522 A MX 2013000522A MX 345697 B MX345697 B MX 345697B
Authority
MX
Mexico
Prior art keywords
rifaximin
formulations
methods
making
relates
Prior art date
Application number
MX2013000522A
Other languages
English (en)
Other versions
MX2013000522A (es
Inventor
Selbo Jon
Teng Jing
A Kabir Mohammed
Golden Pam
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of MX2013000522A publication Critical patent/MX2013000522A/es
Publication of MX345697B publication Critical patent/MX345697B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La presente invención se refiere a nuevas formas de rifaximina que comprenden dispersiones sólidas de rifaximina, métodos para hacer las mismas y a su uso en preparaciones medicinales y métodos terapéuticos.
MX2013000522A 2010-07-12 2011-07-12 Formulaciones de rifaximina y usos de las mismas. MX345697B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36360910P 2010-07-12 2010-07-12
US41905610P 2010-12-02 2010-12-02
PCT/US2011/043769 WO2012009388A1 (en) 2010-07-12 2011-07-12 Formulations of rifaximin and uses thereof

Publications (2)

Publication Number Publication Date
MX2013000522A MX2013000522A (es) 2013-05-01
MX345697B true MX345697B (es) 2017-02-13

Family

ID=45469785

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000522A MX345697B (es) 2010-07-12 2011-07-12 Formulaciones de rifaximina y usos de las mismas.

Country Status (28)

Country Link
US (4) US20120077835A1 (es)
EP (2) EP3750526A1 (es)
JP (1) JP5943915B2 (es)
KR (1) KR101887004B1 (es)
CN (1) CN103228662B (es)
AU (1) AU2011279261B2 (es)
BR (1) BR112013000802B1 (es)
CA (1) CA2804635C (es)
CR (1) CR20130033A (es)
DK (1) DK2593463T3 (es)
EA (1) EA033370B1 (es)
ES (1) ES2801678T3 (es)
GE (2) GEAP202112996A (es)
HU (1) HUE049986T2 (es)
IL (1) IL223725B (es)
LT (1) LT2593463T (es)
MX (1) MX345697B (es)
MY (1) MY165086A (es)
NZ (1) NZ605232A (es)
PH (1) PH12013500082B1 (es)
PL (1) PL2593463T3 (es)
PT (1) PT2593463T (es)
SG (2) SG10201505484RA (es)
SI (1) SI2593463T1 (es)
SM (1) SMT202000390T1 (es)
TN (1) TN2012000611A1 (es)
WO (2) WO2012009387A1 (es)
ZA (1) ZA201300193B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) * 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
HK1204614A1 (en) 2012-01-25 2015-11-27 Salix Pharmaceuticals, Ltd. Rifaximin derivative and uses thereof
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2757135B1 (en) 2013-01-18 2017-11-29 3M Innovative Properties Company Method of bonding parts to a vehicle by an acrylic foam tape
WO2015069305A1 (en) * 2013-11-08 2015-05-14 Tyrx, Inc. Antimicrobial compositions and methods for preventing infection in surgical incision sites
JP6693946B2 (ja) 2014-05-04 2020-05-13 サリックス ファーマスーティカルズ，インコーポレーテッド Ｉｂｓ微生物叢及びその使用
US9938298B2 (en) 2014-05-12 2018-04-10 Alfa Wassermann S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
JP7024248B2 (ja) * 2016-09-01 2022-02-24 大正製薬株式会社 固形製剤
CA3038312A1 (en) * 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
WO2019022784A1 (en) * 2017-07-24 2019-01-31 Acryspharm Llc PHARMACEUTICAL COMPOSITIONS WITH HIGH MEDICATION CHARGE
CN109453166B (zh) * 2018-10-16 2021-03-12 丹诺医药(苏州）有限公司 一种利福霉素-喹嗪酮偶联分子的固体分散体及其应用
CN109453165B (zh) * 2018-10-16 2021-02-05 丹诺医药(苏州）有限公司 一种利福霉素-硝基咪唑偶联分子的固体分散体及其应用
WO2020198136A1 (en) * 2019-03-22 2020-10-01 New York Medical College Use of rifaximin on circulating aged neutrophils in sickle cell disease
CN114401721A (zh) 2019-09-24 2022-04-26 博士医疗爱尔兰有限公司 利福昔明液体制剂
AU2021241001A1 (en) * 2020-03-24 2022-10-20 Bausch Health Ireland Limited Solid dispersions of rifaximin for the treatment of Overt Hepatic Encephalopathy
WO2021209459A1 (en) * 2020-04-13 2021-10-21 Bausch Health Ireland Limited Methods of using solid dispersions of rifaximin for the treatment of sickle cell disease
AU2021298178A1 (en) 2020-06-26 2023-02-02 Bausch Health Ireland Limited Targeted release rifaximin compositions
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease
CN114366717B (zh) * 2022-01-11 2023-06-09 四川农业大学 一种基于egcg纳米粒的肠溶固体分散体颗粒、制备方法及其应用
WO2025151876A1 (en) * 2024-01-11 2025-07-17 Minneamrita Therapeutics Llc Triptolide formulations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1320176B1 (it) 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
CA2448864C (en) * 2001-06-22 2008-04-22 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
PL2011486T5 (pl) * 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
KR100903618B1 (ko) * 2007-10-30 2009-06-18 삼성에스디아이 주식회사 플라즈마 디스플레이 패널
CN102015725B (zh) * 2008-02-25 2014-10-22 萨利克斯药品有限公司 利福昔明的多种形式及其用途
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EP3563850A1 (en) * 2008-02-26 2019-11-06 Salix Pharmaceuticals, Ltd. Methods for treating bowel diseases
EP2105130A1 (de) * 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
CA2745980C (en) * 2008-12-10 2017-10-31 Cipla Limited Rifaximin complexes
UA110199C2 (xx) * 2009-10-27 2015-12-10 Lupin Ltd Тверда дисперсія рифаксиміну
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
PH12012501784A1 (en) * 2010-03-10 2022-10-05 Abbvie Bahamas Ltd Solid compositions

Also Published As

Publication number Publication date
SG10201505484RA (en) 2015-09-29
MX2013000522A (es) 2013-05-01
CR20130033A (es) 2013-04-29
US20120077835A1 (en) 2012-03-29
KR101887004B1 (ko) 2018-08-09
EP2593463A4 (en) 2014-04-23
MY165086A (en) 2018-02-28
AU2011279261B2 (en) 2016-03-31
US20200397904A1 (en) 2020-12-24
US9737610B2 (en) 2017-08-22
PT2593463T (pt) 2020-09-17
BR112013000802A2 (pt) 2016-05-24
WO2012009388A1 (en) 2012-01-19
CN103228662B (zh) 2016-08-10
JP2013532633A (ja) 2013-08-19
GEAP202112996A (en) 2021-09-10
EP3750526A1 (en) 2020-12-16
CA2804635C (en) 2019-09-10
IL223725B (en) 2020-03-31
SMT202000390T1 (it) 2020-09-10
HUE049986T2 (hu) 2020-11-30
SG186981A1 (en) 2013-02-28
PH12013500082A1 (en) 2013-03-11
PL2593463T3 (pl) 2020-11-02
WO2012009387A1 (en) 2012-01-19
SI2593463T1 (sl) 2020-10-30
JP5943915B2 (ja) 2016-07-05
US20170333562A1 (en) 2017-11-23
DK2593463T3 (da) 2020-08-10
PH12013500082B1 (en) 2019-06-28
NZ605232A (en) 2015-09-25
EP2593463A1 (en) 2013-05-22
ZA201300193B (en) 2019-07-31
KR20130098300A (ko) 2013-09-04
TN2012000611A1 (en) 2014-04-01
CN103228662A (zh) 2013-07-31
ES2801678T3 (es) 2021-01-12
US20150133482A1 (en) 2015-05-14
EP2593463B1 (en) 2020-05-06
BR112013000802B1 (pt) 2021-08-31
GEP20227342B (en) 2022-01-25
CA2804635A1 (en) 2012-01-19
EA201370018A1 (ru) 2013-09-30
AU2011279261A1 (en) 2013-01-17
LT2593463T (lt) 2020-08-25
EA033370B1 (ru) 2019-10-31

Similar Documents

Publication Publication Date Title
MX345697B (es) Formulaciones de rifaximina y usos de las mismas.
MX353827B (es) Formas de rifaximina y usos de la misma.
MX2012013945A (es) Nuevas formas de rifaximina y usos de las mismas.
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
MX2015003140A (es) Formulaciones de enzalutamida.
MX369616B (es) Composiciones cutaneas y metodos para su uso.
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
ES2408343R1 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
MX386584B (es) Composiciones de liberación retardada de linaclotida.
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
CL2015001342A1 (es) Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
BR112013003530A2 (pt) ''produto farmacêutico, kit, uso e preparações''
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales
GT201300307A (es) "derivados de pirazol útiles como inhibidores de aldosterona sintasa"
BR112013027219A2 (pt) composição de entacapone, processo para preparar a composição de entacapone, composição farmacêutica, e, uso da composição de entacapone
ES2426017R1 (es) Microemulsión que comprende colagenasa y usos
CU20100260A7 (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos

Legal Events

Date Code Title Description
FG Grant or registration